120 related articles for article (PubMed ID: 7834867)
1. Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets.
Barradas MA; Jagroop IA; Mikhailidis DP
Clin Chim Acta; 1994 Oct; 230(2):157-67. PubMed ID: 7834867
[TBL] [Abstract][Full Text] [Related]
2. Oral naftidrofuryl prevents platelet hyperreactivity ex vivo and inhibits functional desensitization to prostacyclin in hypercholesterolemic rabbits.
Weber AA; Hohlfeld T; Strobach H; Schrör K
J Cardiovasc Pharmacol; 1993 Feb; 21(2):332-8. PubMed ID: 7679170
[TBL] [Abstract][Full Text] [Related]
3. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
Brammer JP; Maguire MH
Br J Pharmacol; 1984 May; 82(1):61-72. PubMed ID: 6428500
[TBL] [Abstract][Full Text] [Related]
4. Shape change and aggregation of blood platelets: interaction between the effects of adenosine and diphosphate, 5-hydroxytryptamine and adrenaline.
Michal F; Motamed M
Br J Pharmacol; 1976 Feb; 56(2):209-18. PubMed ID: 1252669
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of a novel antiplatelet agent, E5510, on collagen-induced platelet-derived growth factor release and aggregation of human platelets in vitro.
Nomoto K; Saeki T; Kogushi M; Kobayashi H; Fujimori T; Yamatsu I
Jpn J Pharmacol; 1993 Jan; 61(1):7-12. PubMed ID: 8437372
[TBL] [Abstract][Full Text] [Related]
6. Effect of naftidrofuryl on platelet aggregation in plasma from aspirin treated patients: an in vitro study.
Le Dévéhat C; Khodabandehlou T; Mosnier M
Clin Hemorheol Microcirc; 2000; 22(3):197-204. PubMed ID: 10976713
[TBL] [Abstract][Full Text] [Related]
7. Effect of naftidrofuryl and aspirin on platelet aggregation in peripheral vascular disease.
Barradas MA; Stansby G; Hamilton G; Mikhailidis DP
In Vivo; 1993; 7(6A):543-8. PubMed ID: 8193274
[TBL] [Abstract][Full Text] [Related]
8. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors.
Kobzar G; Mardla V; Samel N
Platelets; 2011; 22(5):338-44. PubMed ID: 21557683
[TBL] [Abstract][Full Text] [Related]
9. Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.
Serebruany VL; El Mouelhi M; Pfannkuche HJ; Rose K; Marro M; Angiolillo DJ
Am J Ther; 2010; 17(6):543-52. PubMed ID: 19797939
[TBL] [Abstract][Full Text] [Related]
10. Quantitative determination of serotonin released from human platelets.
Marasini B; Biondi ML; Agostoni A
Ric Clin Lab; 1985; 15(3):247-51. PubMed ID: 4081519
[TBL] [Abstract][Full Text] [Related]
11. In vitro effect of reduced glutathione on platelet function.
Pacchiarini L; Tua A; Grignani G
Haematologica; 1996; 81(6):497-502. PubMed ID: 9009436
[TBL] [Abstract][Full Text] [Related]
12. Role of 5-hydroxytryptamine in platelet thrombus formation and mechanisms of inhibition of thrombus formation by 5-hydroxytryptamine2A antagonists in rabbits.
Takano S
Arch Int Pharmacodyn Ther; 1995; 330(3):297-308. PubMed ID: 8836449
[TBL] [Abstract][Full Text] [Related]
13. Platelet aggregation after naftidrofuryl application in vitro and ex vivo.
Kirsten R; Erdeg B; Moxter D; Hesse K; Breidert M; Nelson K
Int J Clin Pharmacol Ther; 1995 Feb; 33(2):81-4. PubMed ID: 7757315
[TBL] [Abstract][Full Text] [Related]
14. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
Krishnamurthi S; Westwick J; Kakkar VV
Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
[TBL] [Abstract][Full Text] [Related]
15. The involvement of 5-HT2-receptor sites in the activation of cat platelets.
De Clerck F; Xhonneux B; Leysen J; Janssen PA
Thromb Res; 1984 Feb; 33(3):305-21. PubMed ID: 6710435
[TBL] [Abstract][Full Text] [Related]
16. Effect of sulphinpyrazone on human platelet aggregation, 5-hydroxytryptamine release and adhesion ex vivo: comparison with naproxen.
Nunn B; James FJ
Br J Clin Pharmacol; 1980 Mar; 9(3):239-45. PubMed ID: 7362733
[TBL] [Abstract][Full Text] [Related]
17. Removal of extraplatelet Na+ eliminates indomethacin-sensitive secretion from human platelets stimulated by epinephrine, ADP, and thrombin.
Connolly TM; Limbird LE
Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5320-4. PubMed ID: 6577431
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of ADP-induced aggregation by 5-HT in rabbit platelets.
Li BY; Bai Y; Li WH
Zhongguo Yao Li Xue Bao; 1998 Jan; 19(1):58-62. PubMed ID: 10375761
[TBL] [Abstract][Full Text] [Related]
19. PDGF modifies phosphoinositide metabolism and inhibits aggregation and release in human platelets.
Bryckaert MC; Rendu F; Tobelem G; Caen J
Biochem Biophys Res Commun; 1986 Feb; 135(1):52-7. PubMed ID: 3006686
[TBL] [Abstract][Full Text] [Related]
20. Differential actions of naftopidil, doxazosin and nifedipine on platelet thromboxane generation and platelet-derived growth factor efflux in vitro.
Alarayyed NA; Prichard BN; Betteridge DJ; Smith CC
Platelets; 2002; 13(5-6):267-71. PubMed ID: 12189011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
